All enquiries concerning your shareholding should be directed to the Company's Registrar, Link Asset Services.
During this challenging time, extra pressure is being put on telephone services.
Therefore, to help those shareholders who need it the most, please can we encourage you to make use of the online Share Portal.
To access your shareholding via the Share Portal click here.
|Admission to AIM||from 7 November 2018 as YGEN
from 4 July 2014 to 6 November 2018 as NIPT
|AIM symbol||YGEN (formerly NIPT)|
|Number of shares in issue||
723,063,283 (Date last updated 23 March 2021)
|% of shares not in public hands||
15.5% (Date last updated 11 August 2020)
|Significant Shareholders with more than 3%:||
(Date last updated 1 October 2020)
|The company is listed on the AIM market of the London Stock Exchange, and is subject to the UK City Code on Takeovers and Mergers.|
Dr Bill Chang holds options over 300,000 new ordinary shares, exercisable at 10.0p, and options over 400,000 new ordinary shares, exercisable at 7.75p, and options over 400,000 new ordinary shares, exercisable at 10.25p. There are no other options, warrants or any other instruments held by significant shareholders.
Life Technologies Limited holds warrants over 20,325,204 new ordinary shares exercisable at 24.6p, warrants over 17,094,018 new ordinary shares exercisable at 11.7p, and warrants over 16,913,319 new ordinary shares exercisable at 11.8p.
Life Technologies Limited holds 41,356,165 ordinary shares which are subject to a lock-in deed until 17 February 2022. There are no other restrictions on the transfer of shares.
Subsequent to the acquisition of Coastal Genomics, Inc completed on 7 August 2020, certain of the former shareholders in that company were issued 10,249,624 new shares in Yourgene Health Canada Investments Ltd, a subsidiary of Yourgene Health plc, incorporated under the laws of British Columbia, Canada. These shares do not carry voting rights, but entitle the holders thereof to participate in any Group dividends on an equivalent basis and are capable of being exchanged for Ordinary Shares in the Company at a price of 18.3 pence per Ordinary Share, subject to lock-in restrictions until 31 March 2023.